Company / Capital Expenditures
aTYR PHARMA INC Capital Expenditures History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$77.0K
FY2025
5-year range
$65.0K / $202.0K
FY2021-FY2025
Trend
+18.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures returned to growth in FY2025 after 2 years of decline, reaching $77,000.
Based on SEC 10-K filings.
$77,000 in FY2025 with a 5-year CAGR of -33.5%.
Declined from $192,000 to $77,000 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -27.5%
- 5-Year CAGR
- -33.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -33.5%, indicating a declining trend.
- In FY2025, capital expenditures increased 18.5% year-over-year.
- Peak capital expenditures was recorded in FY2019.
- Lowest capital expenditures in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -6.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $77.0K | +18.5% |
| FY2024 | $65.0K | -66.1% |
| FY2023 | $192.0K | -5.0% |
| FY2022 | $202.0K | +155.7% |
| FY2021 | $79.0K | -86.7% |
| FY2020 | $594.0K | -54.7% |
| FY2019 | $1.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026